Biocartis strenghtens management team with new CFO
Biocartis announced that Ms. Hilde Windels has been appointed as Chief Financial Officer ("CFO") of the Biocartis group. As of July 1, Hilde Windels will also assume the role of managing director (“Gedelegeerd bestuurder”) of Biocartis NV and director of Biocartis BV. Biocartis NV is a wholly-owned subsidiary of Biocartis SA (Switzerland – Lausanne) located in Mechelen. Biocartis BV is the Dutch subsidiary in Eindhoven.
Hilde brings over 20 years’ experience in corporate finance, capital markets and strategic initiatives. She has extensive experience in financing, investor relations and has been involved in mergers and acquisition processes.
During the last two years, she has been working as independent CFO for a few private biotechnology companies. She is currently on the board of MDX Health (chairing the audit committee) and Flanders Bio, the umbrella organization for the life sciences and biotechnology industry in Flanders.
Hilde was Devgen’s CFO from 1999 until the end of 2008. During that period she was part of the management team that raised EUR 30 M in venture capital money and that took the company public on the Brussels Euronext market in 2005. She was on Devgen’s board from 2001 until the end of 2008.
Previously, she was at ING responsible for commercial banking, in one of the Belgian areas. She holds a degree in economics (“Handelsingenieur”) from the University of Leuven (Belgium).
Other news from the department people
